These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2456 related articles for article (PubMed ID: 8074484)

  • 21. Selective inhibition of proteolytic enzymes in an in vivo mouse model for experimental metastasis.
    Ostrowski LE; Ahsan A; Suthar BP; Pagast P; Bain DL; Wong C; Patel A; Schultz RM
    Cancer Res; 1986 Aug; 46(8):4121-8. PubMed ID: 3089587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
    EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
    Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
    Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in expression of metalloproteinases and plasminogen activators in murine melanocytes and B16 melanoma variants: lack of association with in vitro invasion.
    Huijzer JC; Uhlenkott CE; Meadows GG
    Int J Cancer; 1995 Sep; 63(1):92-9. PubMed ID: 7558459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of serine proteinases and metalloproteinases in organ-cultured human skin. Altered levels in the presence of retinoic acid and possible relationship to retinoid-induced loss of epidermal cohesion.
    Varani J; Burmeister B; Sitrin RG; Shollenberger SB; Inman DR; Fligiel SE; Gibbs DF; Johnson K
    Am J Pathol; 1994 Sep; 145(3):561-73. PubMed ID: 8080040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.
    Fukao H; Hagiya Y; Ueshima S; Okada K; Takaishi T; Izaki S; Matsuo O
    Thromb Haemost; 1996 Feb; 75(2):352-8. PubMed ID: 8815589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta.
    Graham CH; Connelly I; MacDougall JR; Kerbel RS; Stetler-Stevenson WG; Lala PK
    Exp Cell Res; 1994 Sep; 214(1):93-9. PubMed ID: 8082752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
    Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
    Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of sympathetic activity by tissue plasminogen activator is independent of plasminogen and urokinase.
    Schaefer U; Vorlova S; Machida T; Melchor JP; Strickland S; Levi R
    J Pharmacol Exp Ther; 2007 Jul; 322(1):265-73. PubMed ID: 17429057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
    Lijnen HR; Wagner EF; Collen D
    Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
    Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
    Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in the fibrinolytic components of cultured human umbilical vein endothelial cells induced by endotoxin, tumor necrosis factor-alpha and interleukin-1alpha.
    Orbe J; Chordá C; Montes R; Páramo JA
    Haematologica; 1999 Apr; 84(4):306-11. PubMed ID: 10190943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
    Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
    Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of murine B16F10 melanoma plasminogen activator production by a synthetic peptide derived from the laminin A chain.
    Stack MS; Gray RD; Pizzo SV
    Cancer Res; 1993 May; 53(9):1998-2004. PubMed ID: 8481902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator activities in short-term tissue cultures of benign prostatic hyperplasia and prostatic carcinoma.
    Festuccia C; Vincentini C; di Pasquale AB; Aceto G; Zazzeroni F; Miano L; Bologna M
    Oncol Res; 1995; 7(3-4):131-8. PubMed ID: 8555646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional regulation of tissue- and urokinase-type plasminogen activator genes by thrombin in human fetal lung fibroblasts.
    Hayakawa Y; Tazawa S; Ishikawa T; Niiya K; Sakuragawa N
    Thromb Haemost; 1995 Aug; 74(2):704-10. PubMed ID: 8585010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of tetracycline as an inhibitor of matrix metalloproteinase activity secreted by human bone-metastasizing cancer cells.
    Duivenvoorden WC; Hirte HW; Singh G
    Invasion Metastasis; 1997; 17(6):312-22. PubMed ID: 9949290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The characterization of SV40-transformed cell lines derived from mouse teratocarcinoma: growth properties and differentiated characteristics.
    Topp W; Hall JD; Rifkin D; Levine AJ; Pollack R
    J Cell Physiol; 1977 Nov; 93(2):269-76. PubMed ID: 201648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 123.